SFI is developed from Radix Astragali and Codonopsis, which suggests that its effect in the treatment of NSCLC may be related with the above pharmacological Alisertib in vitro activities of Radix Astragali BYL719 ic50 and Codonopsis. However, what are the specific immunological and cytotoxic mechanisms? what are main effective components? Do the interactions between medicines or components exist? These questions are not clear and require further investigation. This systematic review also has limitations. First, allocation concealment and blinding were not described in all included trials, which may result in the emergence of bias, and the overestimation of the efficacy of the treatment group. Second, much of the data on the

patients’ survival was not reported in the included studies, thus the influence that SFI combined with platinum-based chemotherapy had on survival could not be analyzed by this systematic review. Third, funnel plot and Egger’s test suggested publication bias may exist. Given above reasons, the evidence from this study may be insufficient, and should be carefully disseminated to the medical community. However, we all know it is difficult and

this website expensive to carry out clinical trials on advanced NSCLC patients and large, placebo-controlled, double-blind studies are almost impossible. Therefore, trials with above questions may exist in many countries and may be permitted to some extent, but still provide helpful information for clinical practice and drug development. Now it has been increasingly recognized that Western medicine may not be the answer for the treatment of all diseases and sometimes alternative medicines or treatment regimes may prove successful. Therefore, though SFI is a kind of traditional Chinese medicine, the results of this systematic review suggested it may play an important role in the treatment of advanced NSCLC. Conclusions In conclusion,

in this systematic review evidence was found that SFI intervention may increase the efficacy and reduce the toxicity when combined with platinum-based chemotherapy for advanced NSCLC, which would provide important ifenprodil references about how to reduce toxicity and enhance the curative effect of platinum-based chemotherapy for advanced NSCLC. However, limitations remain and the results needs to be further verified by more high-quality trials. Acknowledgements This study was supported by a postgraduate innovation project from Jiangsu Province Education Department, and also supported by National Natural Science Foundation of China (No.30973715). The authors are grateful to the help of Prof Xiu-Lin Gong in writing, and the authors also appreciate the editor board and the reviewers for their work on this paper. References 1. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA: Non-small cell lung cancer: epidemiology risk factors, treatment, and survivorship. Mayo Clin Proc 2008, 83 (5) : 584–594.PubMedCrossRef 2.